Fulcrum Therapeutics, INC. (FULC) — 8-K Filings

8-K Filings (12)

• Fulcrum Therapeutics Enters Material Definitive Agreement — Dec 11, 2025 Risk: medium
  Fulcrum Therapeutics, Inc. announced on December 10, 2025, that it entered into a material definitive agreement. The company, located at 26 Landsdowne Street, C
• Fulcrum Therapeutics Files 8-K — Dec 8, 2025 Risk: low
  Fulcrum Therapeutics, Inc. filed an 8-K on December 8, 2025, reporting on various events. The filing includes information related to financial statements and ex
• 8-K Filing — Aug 28, 2025
• Fulcrum Therapeutics Files 8-K on Shareholder Vote — Jun 27, 2025 Risk: low
  Fulcrum Therapeutics, Inc. filed an 8-K on June 27, 2025, reporting on matters submitted to a vote of security holders as of June 26, 2025. The filing does not
• Fulcrum Therapeutics Terminates Material Definitive Agreement — Mar 4, 2025 Risk: medium
  Fulcrum Therapeutics, Inc. announced on February 26, 2025, the termination of a material definitive agreement. The company, headquartered in Cambridge, Massachu
• Sanofi to Acquire Fulcrum Therapeutics for $805M — Jan 13, 2025 Risk: medium
  Fulcrum Therapeutics, Inc. announced on January 13, 2025, that it has entered into a definitive agreement to be acquired by Sanofi for $8.00 per share in cash,
• Fulcrum Therapeutics Terminates Material Agreement — Dec 23, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. announced on December 18, 2024, the termination of a material definitive agreement. The company, located at 26 Landsdowne Street, Cam
• Fulcrum Therapeutics Announces Board and Compensation Changes — Nov 12, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. announced on November 12, 2024, changes in its board of directors and executive compensation arrangements. The filing details the dep
• Fulcrum Therapeutics Files 8-K — Sep 24, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. filed an 8-K on September 24, 2024, to report on cost associated with exit or disposal activities and financial statements and exhibi
• Fulcrum Therapeutics Files 8-K — Sep 12, 2024 Risk: low
  Fulcrum Therapeutics, Inc. filed an 8-K on September 12, 2024, reporting other events and financial statements. The filing does not contain specific details abo
• Fulcrum Therapeutics Sells $100M in Stock — Aug 22, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. announced on August 21, 2024, that it entered into a securities purchase agreement for the unregistered sale of approximately $100 mi
• Fulcrum Therapeutics Appoints New CMO, Elects Directors — Jun 17, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. announced on June 17, 2024, the appointment of Dr. S. Brooks Marshall as Chief Medical Officer and the election of Dr. Marshall and M

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX